Header Logo

Connection

Mark Tidswell to Follow-Up Studies

This is a "connection" page, showing publications Mark Tidswell has written about Follow-Up Studies.
Connection Strength

0.087
  1. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010 Jan; 38(1):72-83.
    View in: PubMed
    Score: 0.059
  2. Lanspa MJ, Gong MN, Schoenfeld DA, Lee KT, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM, Hough CL, Brower RG, Calfee CS, Hyzy RC, Matthay MA, Miller RR, Steingrub JS, Thompson BT, Miller CD, Clemmer TP, Hendey GW, Huang DT, Mathews KS, Qadir N, Tidswell M. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Ann Am Thorac Soc. 2019 03; 16(3):356-362.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.